Geno J. Merli, MD; Howard H. Weitz, MD
Disclosures: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb, Bayer, sanofi-aventis; Consultancies: Bristol-Myers Squibb, Bayer, sanofi-aventis. Howard H. Weitz, MD, reports that he has no financial relationships or interests to disclose.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Yehia Y. Mishriki, MD, FACP
Lehigh Valley Health Network
January 11, 2015
"Re-balancing" a patient's drug portfolio five years after MI
Perhaps obvious but worth mentioning, the beta blocker should be slowly weaned off over the course of at least 2 weeks. In addition, whether one subscribes to the newer hyperlipidemia guidelines or still goes by the "treat to target" approach, one needs to know what type and what dose of the statin the patient is taking. He should be taking a high dose potent statin (newer guidelines) or achieve an LDL of 70 mg/dl or less (treat to target) which would be ideal (rather than the 90 mg/dl which is acceptable).
Bangladesh Institute of Family Medicine and Research
August 15, 2015
A patient should get lifelong statin for secondary cardiovascular event prevention
Excellent. This patient as per his present condition should continue with low dose aspirin daily (81-162mg) and a statin for whole life. Statin dose may be selected according to ASCVD risk as described by ACC/AHA ATP-IV guideline.I think it is already time to stop “Treat to Target” approach for statin use. If we use “Treat to Target”, question should arise, should I stop statin once target is achieved?Specifically for this patient, statin should be continued indefinitely because he is a patient with established ASCVD, one of the four groups of patients who should get statin as described by ATP-IV guideline.
Merli GJ, Weitz HH. The Consult Guys - Balancing the Medication Portfolio 5 Years After a Heart Attack. Ann Intern Med. ;161:CG12. doi: 10.7326/G14-3012
Download citation file:
Published: Ann Intern Med. 2014;161(12):CG12.
Acute Coronary Syndromes, Cardiology, Coronary Heart Disease, Emergency Medicine.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use